Rithron XR Approval Is Part Of Larger U.S. Vascular Intervention Strategy
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of Biotronik's Rithron XR coronary stent marks a first step in the firm's long-term strategy to enter the U.S. vascular intervention market
You may also be interested in...
Conor Set To Enroll Pivotal U.S. Study For CoStar, Talks Up DES Pipeline
Conor Medsystems expects to begin enrolling a 1,700-patient, U.S. pivotal trial for itsCoStar paclitaxel-eluting, cobalt-chromium coronary stent in the next few weeks
Bioabsorbable Drug-Eluting Stents May Solve Lingering Thrombosis Problem
Late thrombosis caused by drug-eluting stents could be eliminated with the development of new bioabsorbable stents, Ron Waksman, MD, suggested March 29 at the CRT conference in Washington, D.C
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.